

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/246293 A1

(43) International Publication Date
24 November 2022 (24.11.2022)

(51) International Patent Classification:

A61K 35/17 (2015.01) C12N 15/00 (2006.01)
C12N 5/0783 (2010.01)

(21) International Application Number:

PCT/US2022/030394

(22) International Filing Date:

20 May 2022 (20.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/190,685 19 May 2021 (19.05.2021) US
63/255,803 14 October 2021 (14.10.2021) US

(71) Applicant: SANA BIOTECHNOLOGY, INC. [US/US];
188 East Blaine Street, Suite 400, Seattle, WA 98102 (US).

(72) Inventor: SCHREPFER, Sonja; 1 Tower Place, San Ma-
teo, CA 94080 (US).

(74) Agent: MACDOUGALL, Christina A. et al.; Morgan,
Lewis & Bockius LLP, One Market, Spear Street Tower,
San Francisco, CA 94105 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with information concerning request for restoration of the right of priority in respect of one or more priority claims; the decision of the receiving Office regarding the request for restoration is pending and will be published separately once available (Rules 26bis.3 and 48.2(j))

(54) Title: HYPOIMMUNOGENIC RHD NEGATIVE PRIMARY T CELLS

(57) Abstract: Disclosed herein are hypoimmunogenic T cells having reduced expression of RhD antigen for administering to a patient. In some embodiments, the cells are propagated from a primary T cell or a progeny thereof or are derived from an induced pluripotent stem cell (iPSC). In some embodiments, the cells exogenously express CD47 proteins and exhibit reduced expression of MHC class I proteins, MHC class II proteins, or both. In some embodiments, the cells exogenously express one or more chimeric antigen receptors.



WO 2022/246293 A1